MTMatthew Thoenig

Matthew Thoenig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matthew Thoenig has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The SCRIPT Trial: A Randomised Controlled Trial of a Polygenic Risk Score to Tailor Colorectal Cancer Screening in Australian General Practice

    by Sibel Saya, Patty Chondros, Matthew Thoenig, Rachel Brooks, Adrian Laughlin, Madeline Luke, Georgia Ramsay, Richard De Abreu Lourenco, Antonio Ahumada-Canale, Floriy La Rocca, et al.

    Background: Polygenic risk scores (PRS) can predict an individual’s risk of colorectal cancer (CRC) enabling tailoring of screening. The SCRIPT trial tested a complex intervention, including a PRS, in general practice to increase risk-appropriate CRC screening completion.Methods: This was a stratified, individually randomised controlled trial in eight general practices in Victoria, Australia. Patients aged 45-70 were consecutively approached for participation. For those over 50, those due CRC screening were eligible. The SCRIPT intervention comprised a CRC PRS, risk-tailored screening recommendations, and a risk report provided in a consultation and sent to participants’ GP. Control consultations included a discussion and brochure focused on lifestyle CRC risk factors.The primary outcome was the proportion completing risk-appropriate CRC screening by 12 months. In the SCRIPT arm, risk-appropriate screening was defined using PRS- and family history-derived CRC risk; in the control arm, it was defined using family history criteria. National screening guidelines, timing, type and results of previous screening were considered in both arms. Outcome assessors were blind to allocation (no other blinding was possible).Findings: Between 19/04/2021 and 23/08/2022, 276 participants (66% of those eligible) were randomised (138 control, 138 intervention). Three were withdrawn (one in each arm deemed ineligible, one control participant withdrew all data). Intention-to-treat analysis included 137 intervention and 136 control participants. In the SCRIPT arm, 62.8% (n=86) completed risk-appropriate CRC screening within 12 months, compared to 47.8% (n=65) of control participants – an increase of 14.9% (95% confidence interval: 3.5%-26.4%, p=0.012).Interpretation: This is the first trial to show that personalised genomic cancer risk information can be effectively incorporated into a primary care intervention to increase appropriate cancer screening completion. This is a key finding for effective implementation of risk-stratified population cancer screening – ensuring the correct screening is recommended, while optimising participation.

  • Open Access

    The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

    by Sibel Saya, Patty Chondros, Anastasia Abela, Cathrine Mihalopolous, Mary Lou Chatterton, Jane Gunn, Timothy F. Chen, Thomas M. Polasek, Elise Dettmann, Rachel Brooks, et al.

    Background: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. Methods: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18–65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. Discussion: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.